Cargando…
Recent Advances in CRISPR/Cas9-Based Genome Editing Tools for Cardiac Diseases
In the past two decades, genome editing has proven its value as a powerful tool for modeling or even treating numerous diseases. After the development of protein-guided systems such as zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), which for the first time...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537312/ https://www.ncbi.nlm.nih.gov/pubmed/34681646 http://dx.doi.org/10.3390/ijms222010985 |
_version_ | 1784588220217950208 |
---|---|
author | Schreurs, Juliët Sacchetto, Claudia Colpaert, Robin M. W. Vitiello, Libero Rampazzo, Alessandra Calore, Martina |
author_facet | Schreurs, Juliët Sacchetto, Claudia Colpaert, Robin M. W. Vitiello, Libero Rampazzo, Alessandra Calore, Martina |
author_sort | Schreurs, Juliët |
collection | PubMed |
description | In the past two decades, genome editing has proven its value as a powerful tool for modeling or even treating numerous diseases. After the development of protein-guided systems such as zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), which for the first time made DNA editing an actual possibility, the advent of RNA-guided techniques has brought about an epochal change. Based on a bacterial anti-phage system, the CRISPR/Cas9 approach has provided a flexible and adaptable DNA-editing system that has been able to overcome several limitations associated with earlier methods, rapidly becoming the most common tool for both disease modeling and therapeutic studies. More recently, two novel CRISPR/Cas9-derived tools, namely base editing and prime editing, have further widened the range and accuracy of achievable genomic modifications. This review aims to provide an overview of the most recent developments in the genome-editing field and their applications in biomedical research, with a particular focus on models for the study and treatment of cardiac diseases. |
format | Online Article Text |
id | pubmed-8537312 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85373122021-10-24 Recent Advances in CRISPR/Cas9-Based Genome Editing Tools for Cardiac Diseases Schreurs, Juliët Sacchetto, Claudia Colpaert, Robin M. W. Vitiello, Libero Rampazzo, Alessandra Calore, Martina Int J Mol Sci Review In the past two decades, genome editing has proven its value as a powerful tool for modeling or even treating numerous diseases. After the development of protein-guided systems such as zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), which for the first time made DNA editing an actual possibility, the advent of RNA-guided techniques has brought about an epochal change. Based on a bacterial anti-phage system, the CRISPR/Cas9 approach has provided a flexible and adaptable DNA-editing system that has been able to overcome several limitations associated with earlier methods, rapidly becoming the most common tool for both disease modeling and therapeutic studies. More recently, two novel CRISPR/Cas9-derived tools, namely base editing and prime editing, have further widened the range and accuracy of achievable genomic modifications. This review aims to provide an overview of the most recent developments in the genome-editing field and their applications in biomedical research, with a particular focus on models for the study and treatment of cardiac diseases. MDPI 2021-10-12 /pmc/articles/PMC8537312/ /pubmed/34681646 http://dx.doi.org/10.3390/ijms222010985 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Schreurs, Juliët Sacchetto, Claudia Colpaert, Robin M. W. Vitiello, Libero Rampazzo, Alessandra Calore, Martina Recent Advances in CRISPR/Cas9-Based Genome Editing Tools for Cardiac Diseases |
title | Recent Advances in CRISPR/Cas9-Based Genome Editing Tools for Cardiac Diseases |
title_full | Recent Advances in CRISPR/Cas9-Based Genome Editing Tools for Cardiac Diseases |
title_fullStr | Recent Advances in CRISPR/Cas9-Based Genome Editing Tools for Cardiac Diseases |
title_full_unstemmed | Recent Advances in CRISPR/Cas9-Based Genome Editing Tools for Cardiac Diseases |
title_short | Recent Advances in CRISPR/Cas9-Based Genome Editing Tools for Cardiac Diseases |
title_sort | recent advances in crispr/cas9-based genome editing tools for cardiac diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537312/ https://www.ncbi.nlm.nih.gov/pubmed/34681646 http://dx.doi.org/10.3390/ijms222010985 |
work_keys_str_mv | AT schreursjuliet recentadvancesincrisprcas9basedgenomeeditingtoolsforcardiacdiseases AT sacchettoclaudia recentadvancesincrisprcas9basedgenomeeditingtoolsforcardiacdiseases AT colpaertrobinmw recentadvancesincrisprcas9basedgenomeeditingtoolsforcardiacdiseases AT vitiellolibero recentadvancesincrisprcas9basedgenomeeditingtoolsforcardiacdiseases AT rampazzoalessandra recentadvancesincrisprcas9basedgenomeeditingtoolsforcardiacdiseases AT caloremartina recentadvancesincrisprcas9basedgenomeeditingtoolsforcardiacdiseases |